Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-04-19 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于公司2015年度控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 100% confidence The document is an audit report issued by Beijing Tianyuanquan Certified Public Accountants LLP regarding the 2015 fiscal year financial statements of Shandong Ruikang Pharmaceutical Co., Ltd. It includes the auditor's opinion, references to Chinese regulatory requirements for related party transactions, and detailed tables on related party fund occupation. The document is signed and dated April 19, 2016, and contains no indication that it is merely an announcement or certification. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the document fits the category of Audit Report / Information (AR). FY 2015
2016-04-19 Chinese
2015年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2015年度监事会工作报告' which translates to '2015 Supervisory Board Work Report' of Shandong Ruikang Pharmaceutical Co., Ltd. It details the supervisory board's activities, including oversight of financial statements, internal controls, related party transactions, and compliance with laws and regulations for the fiscal year 2015. The document includes summaries of meetings, financial supervision, internal control evaluations, and audit opinions. It is a report from the supervisory board rather than a full annual report or audit report. The content is focused on the supervisory board's work and oversight rather than presenting full financial statements or audit details alone. Given the nature and content, this fits best under the category of Management Reports (MDA), which includes management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the classification is MDA with high confidence.
2016-04-19 Chinese
独立董事2015年度述职报告（金福海）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2015 Annual Work Report" from a specific director of the company. It details the director's attendance at board meetings, opinions on various board matters, participation in committees, and efforts to protect investor rights during the 2015 fiscal year. The content is a narrative report of the director's activities and responsibilities rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings. It is a management-related report focusing on the director's role and duties, which fits best under Board/Management Information (MANG). The document length is 2738 characters, which is consistent with a detailed director's report rather than a brief announcement or a full annual report. Therefore, the classification is MANG with high confidence.
2016-04-19 Chinese
关于召开2015年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2015 Annual General Meeting (AGM) of Shandong Ruikang Pharmaceutical Co., Ltd. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items to be discussed and voted on (including the 2015 annual report and financial statements), and instructions for shareholders on how to participate. The document does not contain the actual annual report or financial statements but rather serves as an official announcement and invitation to the AGM. The presence of detailed voting instructions and proxy forms further confirms this is an AGM notification. Therefore, the document fits the category of AGM Information (AGM-R).
2016-04-19 Chinese
独立董事对续聘会计师事务所的事前认可
Audit Report / Information Classification · 95% confidence The document is a statement from the independent directors of Shandong Ruikang Pharmaceutical Co., Ltd. expressing their prior approval for the reappointment of the accounting firm Beijing Tianyuanquan Certified Public Accountants as the auditor for the 2016 fiscal year. It references regulatory guidance from the China Securities Regulatory Commission and company bylaws. The document is short (666 characters) and primarily contains an approval statement rather than detailed audit results or financial data. It does not contain a full audit report or financial statements but is related to audit matters. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related approvals, excluding full annual reports. The document is not an announcement of a report publication, nor is it a certification letter or a regulatory filing. Hence, the classification is AR with high confidence. FY 2016
2016-04-19 Chinese
第二届监事会第二十八次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 28th meeting of the second Supervisory Board of Shandong Ruikang Pharmaceutical Co., Ltd. It includes approvals of the 2015 Supervisory Board Work Report, the 2015 Annual Report and its summary, the 2015 Financial Final Accounts and 2016 Financial Budget, the 2015 Internal Control Self-Evaluation Report, the 2015 Fundraising Use Special Report, the 2015 Profit Distribution Proposal, and the proposal to reappoint the auditing firm for 2016. The document repeatedly states that the full reports are available on an external website (cninfo.com.cn) and that these resolutions will be submitted to the 2015 Annual General Meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather summarizes the meeting decisions and refers to the full reports elsewhere. The document length is 2737 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of meeting resolutions and report approvals, not the full Annual Report (10-K). It fits best under Regulatory Filings (RNS) as a formal regulatory announcement of supervisory board meeting resolutions and report approvals.
2016-04-19 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.